Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 72,200 shares, a growth of 64.8% from the November 30th total of 43,800 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 72,500 shares, the short-interest ratio is currently 1.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC boosted its stake in Theratechnologies Inc. (NASDAQ:THTX) by 26.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,311 shares of the company’s stock after acquiring an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned 0.29% of Theratechnologies worth $163,000 as of its most recent SEC filing.

Theratechnologies Price Performance

THTX traded down $0.03 during mid-day trading on Friday, hitting $1.80. The stock had a trading volume of 60,248 shares, compared to its average volume of 52,347. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.58. The stock’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $1.34. The firm has a market capitalization of $82.78 million, a price-to-earnings ratio of -18.00 and a beta of 1.43.

Theratechnologies (NASDAQ:THTX) last posted its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $22.60 million during the quarter. During the same period last year, the firm posted ($0.03) earnings per share. As a group, research analysts expect that Theratechnologies will post 0.03 earnings per share for the current fiscal year.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.